| Literature DB >> 33857425 |
Ester Gangoso1, Benjamin Southgate1, Leanne Bradley1, Stefanie Rus1, Felipe Galvez-Cancino2, Niamh McGivern3, Esra Güç4, Chantriolnt-Andreas Kapourani1, Adam Byron3, Kirsty M Ferguson1, Neza Alfazema1, Gillian Morrison1, Vivien Grant1, Carla Blin1, IengFong Sou1, Maria Angeles Marques-Torrejon1, Lucia Conde5, Simona Parrinello6, Javier Herrero5, Stephan Beck7, Sebastian Brandner8, Paul M Brennan1, Paul Bertone9, Jeffrey W Pollard4, Sergio A Quezada2, Duncan Sproul3, Margaret C Frame3, Alan Serrels10, Steven M Pollard11.
Abstract
Glioblastoma multiforme (GBM) is an aggressive brain tumor for which current immunotherapy approaches have been unsuccessful. Here, we explore the mechanisms underlying immune evasion in GBM. By serially transplanting GBM stem cells (GSCs) into immunocompetent hosts, we uncover an acquired capability of GSCs to escape immune clearance by establishing an enhanced immunosuppressive tumor microenvironment. Mechanistically, this is not elicited via genetic selection of tumor subclones, but through an epigenetic immunoediting process wherein stable transcriptional and epigenetic changes in GSCs are enforced following immune attack. These changes launch a myeloid-affiliated transcriptional program, which leads to increased recruitment of tumor-associated macrophages. Furthermore, we identify similar epigenetic and transcriptional signatures in human mesenchymal subtype GSCs. We conclude that epigenetic immunoediting may drive an acquired immune evasion program in the most aggressive mesenchymal GBM subtype by reshaping the tumor immune microenvironment.Entities:
Keywords: DNA methylation; chemokine; epigenetics; glioblastoma; immune evasion; immunoediting; interferon signaling; macrophage; neural stem cell; syngeneic
Year: 2021 PMID: 33857425 DOI: 10.1016/j.cell.2021.03.023
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582